JP2012511014A5 - - Google Patents

Download PDF

Info

Publication number
JP2012511014A5
JP2012511014A5 JP2011539720A JP2011539720A JP2012511014A5 JP 2012511014 A5 JP2012511014 A5 JP 2012511014A5 JP 2011539720 A JP2011539720 A JP 2011539720A JP 2011539720 A JP2011539720 A JP 2011539720A JP 2012511014 A5 JP2012511014 A5 JP 2012511014A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
composition according
compound
cd40l
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011539720A
Other languages
English (en)
Other versions
JP2012511014A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/066715 external-priority patent/WO2010065819A1/en
Publication of JP2012511014A publication Critical patent/JP2012511014A/ja
Publication of JP2012511014A5 publication Critical patent/JP2012511014A5/ja
Pending legal-status Critical Current

Links

Claims (13)

  1. 神経変性障害または神経筋障害を有する患者を治療するための、治療上有効量のCD40およびCD40Lの相互作用を遮断する化合物を含む、医薬組成物。
  2. 化合物が抗CD40L抗体もしくは抗CD40抗体;または抗CD40L抗体もしくは抗CD40抗体の抗体フラグメントである、請求項1に記載の医薬組成物。
  3. 化合物が、Fab、F(ab’)、もしくはF(ab’)抗体フラグメント;一本鎖抗体;またはFab、F(ab’)、もしくはF(ab’)抗体フラグメントまたは一本鎖抗体の融合構築体である、請求項1または2に記載の医薬組成物。
  4. 抗体が、MR1、5c8、IDEC 131/E6040、クローン24−31、ABI793、ImxM90、ImxM91、ImxM92またはSgn−40、およびそれらの抗体フラグメントからなる群から選択される抗CD40L抗体である、請求項2に記載の医薬組成物。
  5. 抗体フラグメントが、Fab、F(ab’)、もしくはF(ab’)フラグメント、一本鎖抗体;または、抗体のFab、F(ab’)、もしくはF(ab’)フラグメントもしくは一本鎖抗体の融合構築体である、請求項4に記載の医薬組成物。
  6. 抗CD40L抗体が、MR1またはその抗体フラグメントである、請求項4に記載の医薬組成物。
  7. 抗CD40L抗体が、5c8またはその抗体フラグメントである、請求項4に記載の医薬組成物。
  8. 化合物が小分子である、請求項1に記載の医薬組成物。
  9. 治療上有効量のCD40およびCD40Lの相互作用を遮断する化合物を、さらに、CD28およびCD86の間またはCD28およびCD80の間の相互作用を遮断する化合物と組み合わせて含む、請求項1−8のいずれか一項記載の医薬組成物。
  10. CD28およびCD86の間またはCD28およびCD80の間の相互作用を遮断する化合物が、CTLA4−Ig融合タンパク質である、請求項9に記載の医薬組成物。
  11. CD28およびCD86の間またはCD28およびCD80の間の相互作用を遮断する化合物が、アバタセプト、ベラタセプトまたはグリキシマブである、請求項9に記載の医薬組成物。
  12. 障害が、パーキンソン病、筋萎縮性側索硬化症、多巣性運動ニューロパチー、原発性側索硬化症、脊髄性筋萎縮症、ケネディ病または脊髄小脳失調症である、請求項1−11のいずれか一項記載の医薬組成物。
  13. 障害が筋萎縮性側索硬化症である、請求項12に記載の医薬組成物。
JP2011539720A 2008-12-05 2009-12-04 神経変成疾患を治療する方法 Pending JP2012511014A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12012108P 2008-12-05 2008-12-05
US61/120,121 2008-12-05
PCT/US2009/066715 WO2010065819A1 (en) 2008-12-05 2009-12-04 Method for the treatment of neurodegenerative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015095123A Division JP6027646B2 (ja) 2008-12-05 2015-05-07 神経変性疾患を治療する方法

Publications (2)

Publication Number Publication Date
JP2012511014A JP2012511014A (ja) 2012-05-17
JP2012511014A5 true JP2012511014A5 (ja) 2013-01-31

Family

ID=41824732

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011539720A Pending JP2012511014A (ja) 2008-12-05 2009-12-04 神経変成疾患を治療する方法
JP2015095123A Active JP6027646B2 (ja) 2008-12-05 2015-05-07 神経変性疾患を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015095123A Active JP6027646B2 (ja) 2008-12-05 2015-05-07 神経変性疾患を治療する方法

Country Status (6)

Country Link
US (1) US8435514B2 (ja)
EP (1) EP2367849B1 (ja)
JP (2) JP2012511014A (ja)
DK (1) DK2367849T3 (ja)
ES (1) ES2650267T3 (ja)
WO (1) WO2010065819A1 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9044459B2 (en) * 2008-12-05 2015-06-02 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
WO2012125569A2 (en) 2011-03-11 2012-09-20 Beth Israel Deaconess Medical Center, Inc. Anti-cd40 antibodies and uses thereof
CN113461819B (zh) 2011-04-29 2024-01-02 埃派斯进有限公司 抗-cd40抗体及其使用方法
DK2914627T3 (da) 2012-10-30 2021-07-12 Apexigen Inc Anti-cd40-antistoffer og fremgangsmåder til anvendelse
GB201501613D0 (en) * 2015-01-30 2015-03-18 Ucb Biopharma Sprl Treatment of autoimmune disorders with CD154 antibodies
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
AU2016315873B2 (en) 2015-09-04 2022-08-18 Primatope Therapeutics Inc. Humanized anti-CD40 antibodies and uses thereof
DK3359688T3 (da) 2015-10-05 2021-08-23 Biogen Ma Inc Molekylære signaturer til anvendelse til diagnose og analyse af respons på behandling af autoimmune sygdomme
MA50435A (fr) 2017-05-24 2020-09-02 Als Therapy Development Inst Anticorps anti-ligand anti-cd40 thérapeutiques

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
TR199902192T2 (xx) 1997-01-10 1999-12-21 Biogen,Inc Anti-CDL40 bile�iklerinin tedavi ama�l� uygulama y�ntemleri
TR199902191T2 (xx) 1997-01-10 1999-12-21 Biogen, Inc. Anti-CD40L bile�ikleri ile lupus nefritis tedavisi
GB0006398D0 (en) 2000-03-16 2000-05-03 Novartis Ag Organic compounds
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
AU2001287041B2 (en) 2000-09-01 2006-06-08 Biogen Idec Ma Inc. Pyridine derivatives useful as CD40:CD154 binding interruptor compounds and use thereof to treat immunological complications
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
US20040146949A1 (en) 2002-10-25 2004-07-29 Jun Tan Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006138316A2 (en) 2005-06-14 2006-12-28 Biogen Idec Ma Inc. Methods for delivering molecules to the central nervous system

Similar Documents

Publication Publication Date Title
JP2012511014A5 (ja)
HRP20191342T1 (hr) Anti-phf-tau antitijela i njihove upotrebe
JP2009535021A5 (ja)
JP2010526028A5 (ja)
JP2018520650A5 (ja)
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
JP2010532764A5 (ja)
WO2006089133A8 (en) Anti-cd19 antibodies and uses in oncology
JP2008516970A5 (ja)
JP2016537966A5 (ja)
JP2013520996A5 (ja)
RU2015143886A (ru) Антитела к тау и способы применения
WO2007062245A3 (en) Human monoclonal antibody human cd134 (ox40) and methods of making and using same
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
JP2011514150A5 (ja)
NZ594315A (en) Antibody molecules having specificity for human ox40
WO2006099875A8 (en) Antibodies against cd38 for treatment of multiple myeloma
NZ610734A (en) Human antibodies to the glucagon receptor
JP2013538553A5 (ja)
WO2008156713A3 (en) Anti-cd20 therapeutic compositions and methods
TW200740844A (en) Novel MAdCAM antibodies
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
JP2016513682A5 (ja)
JP2012502649A5 (ja)
WO2006128103A3 (en) Humanized anti-cd40 antibodies and their methods of use